ClinicalTrials.gg
TerminatedNCT00617890Updated Aug 23, 2018Results posted

A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)

A Phase 2 interventional study of robatumumab in Osteosarcoma, Sarcoma, Ewing's and Peripheral Neuroectodermal Tumor, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2018-08-23.

Primary conditionSarcoma, EwingRegistry: OsteosarcomaReclassifiedWhy we changed it
Registry
Osteosarcoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Sarcoma, Ewing
Why
  1. The study's listed conditions name Sarcoma, Ewing, a narrower term within Osteosarcoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
The study was prematurely terminated for strategic reasons, not for a safety concern.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
219
Allocation
Randomized
Ages
4 Years and older
Sex
All
01

Study summary

Participants with relapsed osteosarcoma that can be treated with surgery will be randomized to robatumumab administered intravenously (IV) at one of two dose levels. These participants will first receive robatumumab, have surgery performed, and continue to receive treatment every two weeks until a year of dosing, or until disease progression.

Participants with unresectable osteosarcoma or Ewing Sarcoma will receive robatumumab IV once every two weeks until disease progression. Participants who achieve a complete response (CR) or partial response (PR) after tumor evaluations may undergo surgical resection. After surgery, participants are eligible to receive 10 mg/kg robatumumab until disease recurrence/progression or one year of total dosing, whichever occurs first.

Read the detailed description

Participants with resectable osteosarcoma will be randomized to one of two dose levels of robatumumab to be given intravenously. These participants will first receive robatumumab according to randomized treatment, and have surgery performed 10 to 14 days after initial dosing. Participants will be allowed to recover from surgery four to six weeks prior to additional robatumumab administration at their randomized dose level. robatumumab will then be administered on the same calendar day once every two weeks. Participants will continue to receive robatumumab until disease recurrence, or until completing a year of dosing at the same dose level assigned, whichever occurs first.

Participants with unresectable osteosarcoma or Ewing Sarcoma will be assigned treatment to robatumumab IV administered once every two weeks and will continue to receive robatumumab until disease progression. Participants who achieve a CR or PR after tumor evaluations may undergo surgical resection. After surgery, participants are eligible to receive 10 mg/kg robatumumab until disease recurrence/progression or one year of total dosing, whichever occurs first.

02

Conditions studied

  • Osteosarcoma
  • Sarcoma, Ewing's
  • Peripheral Neuroectodermal Tumor

Browse trials for

Keywords

  • anti-IGF-1R
03

In context

Sarcoma, Ewing Reclassified

250 studies on the registry are indexed under Sarcoma, Ewing; 69 are open to participants now.

This study's enrollment of 219 is above the median of 36 across 204 interventional studies indexed under Sarcoma, Ewing.

Browse Sarcoma, Ewing studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Compared within Sarcoma, Ewing, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteosarcoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A participant must be 11 years of age or older and may be of any race, and gender; participants between 4 and 10 years of age, inclusive, may be considered on a site-by-site basis.
  • A participant must have a diagnosis of confirmed osteosarcoma or Ewing sarcoma;
  • A participant with either:

    • and resectable osteosarcoma
    • relapsed and unresectable osteosarcoma that is refractory to standard therapy, ie. has relapsed after prior systemic treatment with active chemotherapy agents
    • Ewing sarcoma that is refractory to standard systemic therapies
  • A participant >16 years of age must have an (ECOG) performance status of \<=2; a participant \<=16 years of age must have a performance status between 50% and 100% or a Lansky play scale between 50% and 100%
  • A participant must have adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • A participant with a history of another (with the exception of non-melanoma skin cancer or carcinoma in situ of the cervix treated with curative intent at least 2 years prior to start of treatment, or other adequately treated malignancy for which the subject has been disease free for >=5 years)
  • A participant who has known treated or untreated , or a central nervous system lesion
  • A participant with a history of uncontrolled diabetes mellitus
  • A participant with a recent myocardial infarction (within the past year); or a participant who at the time of Screening presents with unstable or uncontrolled angina, (NYHA) Class III or IV congestive heart failure, uncontrolled hypertension, cardiac dysrhythmia or clinically significant (ECG) abnormality
  • A participant with an active infection
  • A participant with clinically significant hepatitis at Screening, or a participant who is antibody positive, surface antigen positive, or (HIV) seropositive
  • A participant who has been treated with an anti-insulin-like growth factor receptor 1 (anti-IGF-1R)- targeted drug or antibody
  • A participant with known to other antibodies, or any accompanying associated with these medications.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
219 participants (actual)

Study arms

  • Experimental
    Group 1: 0.3 mg/kg

    Participants received robatumumab 0.3 mg/kg intravenously (IV) as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 0.3 mg/kg on the same calendar day (± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.

    Biological: robatumumab

  • Experimental
    Group 1: 10 mg/kg

    Participants who received robatumumab 10 mg/kg IV as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 10 mg/kg on the same calendar day (± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.

    Biological: robatumumab

  • Experimental
    Group 2: 10 mg/kg

    Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with relapsed and unresectable osteosarcoma refractory to prior chemotherapy with a platinum- and doxorubicin-containing regimen.

    Biological: robatumumab

  • Experimental
    Group 3: 10 mg/kg

    Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with Ewing sarcoma refractory to prior treatment with at least 3 of the following agents: ifosfamide, etoposide, cyclophosphamide, doxorubicin, or vincristine.

    Biological: robatumumab

Interventions

  • Biologicalrobatumumab

    Robatumumab IV every two weeks until disease progression.

    Also known as: SCH 717454, SCH 717454 (19D12), MK-7454

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving a Complete Response or Partial Response (Group 3 Only)

    This is a measure of the number of participants with a complete response (CR) or partial response (PR) to therapy, confirmed by central review. Response was based on Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization (WHO) criteria.

    Time frame: Up to 1 year following the start of study therapy

  2. Number of Participants With >= 25% Change in Tumor Proliferation After Exposure to Robatumumab (Group 1 Only)

    Tumor proliferation was measured using Ki-67 levels. Ki-67 is nuclear protein associated with cellular proliferation.

    Time frame: Approximately 14 days

  3. Number of Participants Achieving a Complete Response, a Partial Response, or Stable Disease (Group 2 Only)

    Responses to treatment (complete response, partial response, or stable disease) confirmed by central review for Participants in Group 2. Response was based on Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization (WHO) criteria.

    Time frame: Up to 1 year following the start of study therapy

Secondary outcomes

  1. Overall Survival

    This is a measure of the number of participants known to be alive at the time of data analysis for this study.

    Time frame: From start of treatment until death or data analysis cut off (Up to 3.4 years)

  2. Time Until Tumor Relapse (Group 1 Only)

    This is a measure of the time from the start of the study to documented relapse of disease.

    Time frame: From start of treatment until relapse or data analysis cut off (Up to 3.4 years)

  3. Area Under the Concentration-time Curve (AUC) of Serum Levels of Robatumumab (Group 1 Only)

    Time frame: End of infusion on Day 1, and then prior to surgery, before and after the 2nd, 3rd, and 8th doses (up to 20 weeks)

  4. Incidence of Anti-robatumumab Antibodies

    For biological agents, it is possible for the host (participant) to develop antibodies to the agent. This outcome measure was planned to find out the number of participants who developed the antibodies after treatment with robatumumab.

    Time frame: Up to 2 years

  5. Number of Participants Experiencing Treatment-Emergent Adverse Events

    An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment. Treatment-emergent adverse events are those that occur after participants have received study treatment, or existing adverse events that occurred during screening that increase in severity after study treatment. Adverse events in the Group 1: 0.3 mg/kg arm that occurred after switching to the 10 mg/kg dose are displayed under the originally assigned treatment.

    Time frame: Up to 2 years

  6. Time to Disease Progression (Groups 2 and 3 Only)

    This is a measure of the time from the start of the study to the time of documented disease progression.

    Time frame: From the start of treatment until disease progression or data analysis cut off (Up to 3.4 years)

  7. Overall Survival (Groups 2 and 3 Only)

    This is a measure of the time of survival from first dose to documentation of death

    Time frame: From start of treatment until death or data analysis cut off (Up to 3.4 years)

  8. Duration of Response (Groups 2 and 3 Only)

    This is a measure of the amount of time in which the tumor responded to therapy.

    Time frame: From time of documented response until disease progression or data analysis cut off (Up to 3.4 years)

07

Results

Posted Dec 11, 2015
Limitations and caveats
The study was stopped prematurely for administrative reasons; not all planned endpoints were analyzed.

Participant flow

Participant flow — Overall Study
MilestoneGroup 1: 0.3 mg/kgGroup 1: 10 mg/kgGroup 2: 10 mg/kgGroup 3: 10 mg/kg
Started353335116
Received treatment343334115
Completed4501
Not completed312835115
Withdrew: Treatment ongoing at data cut-off0005
Withdrew: Lack of efficacy23263097
Withdrew: Lost to follow-up0012
Withdrew: Withdrawal by subject4102
Withdrew: Protocol violation2100
Withdrew: Adverse event1038
Withdrew: Not treated1011

Outcome measures

PrimaryNumber of Participants Achieving a Complete Response or Partial Response (Group 3 Only)

This is a measure of the number of participants with a complete response (CR) or partial response (PR) to therapy, confirmed by central review. Response was based on Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization (WHO) criteria.

Time frame:
Up to 1 year following the start of study therapy
Reported as:
Number · Participants
Number of Participants Achieving a Complete Response or Partial Response (Group 3 Only)
ParticipantsGroup 3: 10 mg/kg
Number of Participants Achieving a Complete Response or Partial Response (Group 3 Only)6
PrimaryNumber of Participants With >= 25% Change in Tumor Proliferation After Exposure to Robatumumab (Group 1 Only)

Tumor proliferation was measured using Ki-67 levels. Ki-67 is nuclear protein associated with cellular proliferation.

Time frame:
Approximately 14 days

No measurements were reported for this outcome.

PrimaryNumber of Participants Achieving a Complete Response, a Partial Response, or Stable Disease (Group 2 Only)

Responses to treatment (complete response, partial response, or stable disease) confirmed by central review for Participants in Group 2. Response was based on Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization (WHO) criteria.

Time frame:
Up to 1 year following the start of study therapy
Reported as:
Number · Participants
Number of Participants Achieving a Complete Response, a Partial Response, or Stable Disease (Group 2 Only)
ParticipantsGroup 2: 10 mg/kg
Number of Participants Achieving a Complete Response, a Partial Response, or Stable Disease (Group 2 Only)6
SecondaryOverall Survival

This is a measure of the number of participants known to be alive at the time of data analysis for this study.

Time frame:
From start of treatment until death or data analysis cut off (Up to 3.4 years)
Reported as:
Number · Participants
Overall Survival
ParticipantsGroup 1: 0.3 mg/kgGroup 1: 10 mg/kgGroup 2: 10 mg/kgGroup 3: 10 mg/kg
Overall Survival1716728
SecondaryTime Until Tumor Relapse (Group 1 Only)

This is a measure of the time from the start of the study to documented relapse of disease.

Time frame:
From start of treatment until relapse or data analysis cut off (Up to 3.4 years)

No measurements were reported for this outcome.

SecondaryArea Under the Concentration-time Curve (AUC) of Serum Levels of Robatumumab (Group 1 Only)
Time frame:
End of infusion on Day 1, and then prior to surgery, before and after the 2nd, 3rd, and 8th doses (up to 20 weeks)

No measurements were reported for this outcome.

SecondaryIncidence of Anti-robatumumab Antibodies

For biological agents, it is possible for the host (participant) to develop antibodies to the agent. This outcome measure was planned to find out the number of participants who developed the antibodies after treatment with robatumumab.

Time frame:
Up to 2 years

No measurements were reported for this outcome.

SecondaryNumber of Participants Experiencing Treatment-Emergent Adverse Events

An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment. Treatment-emergent adverse events are those that occur after participants have received study treatment, or existing adverse events that occurred during screening that increase in severity after study treatment. Adverse events in the Group 1: 0.3 mg/kg arm that occurred after switching to the 10 mg/kg dose are displayed under the originally assigned treatment.

Time frame:
Up to 2 years
Reported as:
Number · Participants
Number of Participants Experiencing Treatment-Emergent Adverse Events
ParticipantsGroup 1: 0.3 mg/kgGroup 1: 10 mg/kgGroup 2: 10 mg/kgGroup 3: 10 mg/kg
Number of Participants Experiencing Treatment-Emergent Adverse Events313031112
SecondaryTime to Disease Progression (Groups 2 and 3 Only)

This is a measure of the time from the start of the study to the time of documented disease progression.

Time frame:
From the start of treatment until disease progression or data analysis cut off (Up to 3.4 years)

No measurements were reported for this outcome.

SecondaryOverall Survival (Groups 2 and 3 Only)

This is a measure of the time of survival from first dose to documentation of death

Time frame:
From start of treatment until death or data analysis cut off (Up to 3.4 years)
Reported as:
Median · Months
Overall Survival (Groups 2 and 3 Only)
MonthsGroup 2: 10 mg/kgGroup 3: 10 mg/kg
Overall Survival (Groups 2 and 3 Only)8.18 (2.96 to 10.58)6.93 (4.93 to 11.10)
SecondaryDuration of Response (Groups 2 and 3 Only)

This is a measure of the amount of time in which the tumor responded to therapy.

Time frame:
From time of documented response until disease progression or data analysis cut off (Up to 3.4 years)

No measurements were reported for this outcome.

Adverse events

Collected over Adverse events are reported from enrollment up to 5 weeks after the end of treatment (up to 2 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: 0.3mg/kg—17/34 (50%)28/34 (82.4%)
Group 1: 10mg/kg—8/33 (24.2%)30/33 (90.9%)
Group 2: 10mg/kg—12/34 (35.3%)29/34 (85.3%)
Group 3: 10mg/kg—57/115 (49.6%)104/115 (90.4%)
Most frequent serious events
Showing 10 of 116
Most frequent serious events
EventGroup 1: 0.3mg/kgGroup 1: 10mg/kgGroup 2: 10mg/kgGroup 3: 10mg/kg
PNEUMOTHORAXRespiratory, thoracic and mediastinal disorders4/341/330/341/115
PAINGeneral disorders0/341/330/3411/115
RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders3/341/330/345/115
PYREXIAGeneral disorders1/341/330/347/115
FEBRILE NEUTROPENIABlood and lymphatic system disorders2/340/330/340/115
DYSPNOEARespiratory, thoracic and mediastinal disorders0/340/332/343/115
RESPIRATORY DISTRESSRespiratory, thoracic and mediastinal disorders0/340/330/346/115
THROMBOCYTOPENIABlood and lymphatic system disorders0/340/331/344/115
CHEST PAINGeneral disorders0/340/331/344/115
CONSTIPATIONGastrointestinal disorders0/341/330/342/115
Most frequent other events
Showing 10 of 83
Most frequent other events
EventGroup 1: 0.3mg/kgGroup 1: 10mg/kgGroup 2: 10mg/kgGroup 3: 10mg/kg
NAUSEAGastrointestinal disorders13/3412/335/3435/115
PROCEDURAL PAINInjury, poisoning and procedural complications13/346/331/342/115
PYREXIAGeneral disorders9/3411/336/3421/115
CONSTIPATIONGastrointestinal disorders9/349/333/3434/115
COUGHRespiratory, thoracic and mediastinal disorders10/347/336/3416/115
VOMITINGGastrointestinal disorders9/348/333/3425/115
HEADACHENervous system disorders9/347/337/3424/115
DIARRHOEAGastrointestinal disorders3/346/332/3429/115
DECREASED APPETITEMetabolism and nutrition disorders5/344/334/3427/115
FATIGUEGeneral disorders7/347/337/3423/115

Baseline characteristics

Three participants did not receive study treatment but are included in the baseline population.

Age, Continuous
Age, Continuous(Years)Group 1: 0.3 mg/kgGroup 1: 10 mg/kgGroup 2: 10 mg/kgGroup 3: 10 mg/kgTotal
Mean23.7 ± 15.520.1 ± 10.327.5 ± 15.324.6 ± 11.424.3 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: 0.3 mg/kgGroup 1: 10 mg/kgGroup 2: 10 mg/kgGroup 3: 10 mg/kgTotal
Female1413114381
Male21202473138
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Anderson PM, Bielack SS, Gorlick RG, Skubitz K, Daw NC, Herzog CE, Monge OR, Lassaletta A, Boldrini E, Papai Z, Rubino J, Pathiraja K, Hille DA, Ayers M, Yao SL, Nebozhyn M, Lu B, Mauro D. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. Pediatr Blood Cancer. 2016 Oct;63(10):1761-70. doi: 10.1002/pbc.26087. Epub 2016 Jun 30. PubMed 27362300 ↗
  • Asmane I, Watkin E, Alberti L, Duc A, Marec-Berard P, Ray-Coquard I, Cassier P, Decouvelaere AV, Ranchere D, Kurtz JE, Bergerat JP, Blay JY. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur J Cancer. 2012 Nov;48(16):3027-35. doi: 10.1016/j.ejca.2012.05.009. Epub 2012 Jun 7. PubMed 22682017 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2008 to primary completion in Aug 2011, 42 months.

Results were first posted in Dec 2015, 4 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2008
First posted
Feb 18, 2008
StartActual
Feb 1, 2008
Primary completionActual
Aug 31, 2011
CompletionActual
Aug 31, 2013
Results first posted
Dec 11, 2015
Last update
Aug 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00617890
Responsible party
Sponsor
First posted
Feb 18, 2008
Start date
Feb 1, 2008
Primary completion
Aug 31, 2011
Completion
Aug 31, 2013
Results posted
Dec 11, 2015
Last update
Aug 23, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion